US Stock MarketDetailed Quotes

TRVI Trevi Therapeutics

Watchlist
  • 2.675
  • +0.095+3.68%
Trading Apr 18 12:04 ET
184.47MMarket Cap-9224P/E (TTM)

About Trevi Therapeutics Company

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization Haduvio to treat serious neurologically mediated conditions. It includes treatment of chronic pruritus associated with prurigo nodularis and chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson’s disease. The company was founded by Thomas R. Sciascia and Jennifer L. Good in March 2011 and is headquartered in New Haven, CT.

Company Profile

SymbolTRVI
Company NameTrevi Therapeutics
Listing DateMay 7, 2019
Issue Price10.00
Founded2011
CEOMs. Jennifer L. Good
MarketNASDAQ
Employees25
Securities TypeOrdinary Shares
Fiscal Year Ends12-31
Address195 Church Street,14th floor
CityNew Haven
ProvinceConnecticut
CountryUnited States of America
Zip Code06510
Phone1-203-304-2499
Websitehttp://www.trevitherapeutics.com

Company Executives

  • Name
  • Position
  • Salary
  • Jennifer L. Good
  • President, Chief Executive Officer and Director
  • 1.53M
  • Dr. Thomas R. Sciascia,M.D.
  • Chief Scientific Officer
  • 717.54K
  • Lisa Delfini
  • Chief Financial Officer
  • --
  • Farrell Simon
  • Chief Commercial Officer
  • --
  • David J. Clark
  • Chief Medical Officer
  • --
  • Christopher Galletta
  • Controller and Principal Accounting Officer
  • --
  • Dr. David P. Meeker,M.D.
  • Chairman of the Board
  • 102.77K
  • Dominick C. Colangelo
  • Independent Director
  • 85.27K
  • Dr. James V. Cassella,PhD
  • Independent Director
  • 76.77K
  • Michael T. Heffernan, R.Ph.
  • Lead Independent Director
  • 90.27K
  • Anne M. Vanlent
  • Independent Director
  • 91.77K
  • Edward T. Mathers
  • Independent Director
  • 77.77K

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
%Chg